Liquidia plans PH-ILD enrollment completion in 2028, L606 NDA submission in 2029
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Liquidia (LQDA) Q3 2026 MANAGEMENT VIEW * "YUTREPIA has delivered 5 consecutive quarters of growth in prescriptions, revenue and adjusted EBITDA" (CEO Roger Jeffs), and "with last month's settlement; the litigation overhang is behind us" (CEO Jeffs). *…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong quarterly revenue growth and settled litigation are positive for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third quarter net product sales grew 31% to $222.7 million.
- 02Management says the litigation overhang is behind the company after a recent settlement.
- 03Monthly shipments to patients in October reached their highest level since launch.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets